Vitiligo is not dangerous and it is not contagious, which is exactly why it went under-treated for so long. It takes pigment, not tissue. For most of the last century a diagnosis came with a shrug and a tube of steroid cream. That has changed in the past three years, and the change is worth reporting plainly, because it sits behind a search term - “vitiligo treatment market” - that people actually type.
What the market numbers say, and who is counting
The figure that circulates online comes from Renub Research, which values the global vitiligo market at about US$ 1.21 billion in 2025 and projects US$ 1.93 billion by 2034, a compound annual growth rate of 5.32 percent. Renub segments the market by treatment type, from topical drugs to light therapy to surgery, and names the companies with a stake in it: Incyte, Bristol-Myers Squibb, Pfizer, Astellas, Clinuvel and Dr Reddy’s Laboratories.
I want to be careful with a number like that. A single research house’s projection is a sales document as much as a measurement, and the vitiligo “market” it sizes is mostly drug and device revenue in wealthy countries, not a headcount of patients treated. Roughly one to two percent of people worldwide have vitiligo; the paying market is a fraction of them. The useful signal in the figure is not the decimal. It is the direction. Money is moving into a condition that used to attract almost none, and the reason is a genuine shift in what doctors can offer.
The treatment story is real, and recent
The turning point has a date. On 18 July 2022 the US Food and Drug Administration approved topical ruxolitinib, sold as Opzelura, for nonsegmental vitiligo in patients 12 and older. It was the first drug the agency cleared to restore lost pigment rather than merely slow the spread. Ruxolitinib is a Janus kinase inhibitor; it interrupts the immune signalling that destroys melanocytes, the cells that make pigment. The European Medicines Agency followed in 2023.
The results are meaningful without being miraculous, and the American Academy of Dermatology states them soberly. In the pivotal trials about 30 percent of patients regained 75 percent of facial pigment by week 24, and roughly 15 percent regained 90 percent. Treatment works slowly, colour returns “a little at a time,” and it does not cure anything. Stop applying the cream and about 40 percent of patients lose colour again within a year. That is the honest frame for anyone selling hope on this condition.
Older tools still do most of the work. Narrowband ultraviolet B phototherapy remains a standard of care, endorsed in the Journal of the American Academy of Dermatology by the Vitiligo Working Group, which had to write dosing guidelines precisely because practice varied so widely across the world. Phototherapy means a light box two or three times a week for months, in a clinic or at home. Corticosteroids and calcineurin inhibitors fill in around it, and for stable disease there is surgery, grafting or melanocyte transplantation, which dermatologists avoid while the condition is still active.
Why a skin condition becomes a travel niche
Here is where the patient-travel angle earns its place, and it is not the glossy one the old market copy implied. People travel for vitiligo care for two unglamorous reasons: access and cost.
The new cream illustrates the access gap. Opzelura carries a US list price around US$ 2,000 for a 60-gram tube, and a face-and-hands regimen burns through tubes. Insurance and copay cards blunt that inside the United States; outside a handful of rich markets the drug is either unavailable or unaffordable. Phototherapy’s real cost, meanwhile, is not the machine but the calendar - dozens of clinic visits that a working patient in a country with few phototherapy units simply cannot make.
Into that gap steps Cuba, which has run a vitiligo destination programme for decades. Its Placental Histotherapy Centre in Havana treats foreign patients with Melagenina Plus, a human placental extract, and reports repigmentation in 86 percent of cases. I read that number the way I read Renub’s, with a hand on my wallet. OnCubaNews reports that Melagenina is only now going through a Phase 3 trial to meet international certification, and even its own clinicians say it “does not work miracles” and works best in patients under 15 with limited depigmentation. A treatment that has been marketed to medical travellers for forty years and is only now running a registration trial tells you how thin the evidence has been under the marketing.
So the niche is real but small, and it splits in two. There is evidence-based care that travels because it is expensive at home, a patient flying somewhere with cheap, well-run phototherapy and a competent dermatologist. And there is hope-based care that travels because it promises what licensed medicine will not, which is where the buyer needs to read the trial data rather than the brochure. Anyone facilitating this trade is choosing which of those two businesses they are in.
What This Means
The vitiligo story is a good test of whether a treatment market is worth chasing. The demand is durable. People search for this because pigment loss is visible, permanent without care, and now, for the first time, partly reversible. The medicine finally has something to sell that works, which is what makes the market real rather than invented. But the honest version of the pitch is narrow: one licensed cream with a 30 percent facial response, a phototherapy regimen measured in months, and no cure at the end of any of it. A place that wants this patient should compete on the boring things, a dermatologist who will state the odds, a phototherapy schedule the patient can actually keep, and a price that beats staying home, and leave the 86 percent miracle to the clinics still selling it. The patients who travel well for vitiligo will be the ones who were told the truth before they booked.
